H.C. Wainwright Thinks Aslan Pharmaceuticals Ltd’s Stock is Going to Recover


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals Ltd (ASLN), with a price target of $8.50. The company’s shares closed on Friday at $3.59, close to its 52-week low of $2.51.

Selvaraju commented:

“Our price target is derived from a market value of the firm at $290M. This valuation includes a discounted cash flow analysis based asset value of $300M for varlitinib and ASLAN003, using a 15% discount rate and 0.5% terminal growth rate and excluding $10M debt.”

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -8.6% and a 34.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aslan Pharmaceuticals Ltd with a $8.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $10.44 and a one-year low of $2.51. Currently, Aslan Pharmaceuticals Ltd has an average volume of 27.35K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts